Screener
Aclaris Therapeutics ACRS Drug Candidate Ati9494 — Research And Development Project Spend
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept acrs:ResearchAndDevelopmentProjectSpend.
The source filing: Aclaris Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-092065
| (In thousands) | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Bosakitug | 3,335 | 2,847 | 6,476 | 6,231 |
| ATI-052 | 4,899 | 1,418 | 8,080 | 2,037 |
| Modzatinib | 370 | 1,118 | 861 | 2,926 |
| ATI-9494 | 3,056 | 871 | 5,281 | 1,549 |
| Discovery | 1,972 | 749 | 3,411 | 1,417 |
| Total research and development project expense(1) | 13,632 | 7,003 | 24,109 | 14,160 |
| Personnel | 3,036 | 2,984 | 6,317 | 5,911 |
| Other research and development(2) | 1,398 | 1,462 | 3,297 | 2,962 |
Item 1. Financial Statements
FAQ
- What is Aclaris Therapeutics's drug candidate ati9494 — research and development project spend?
- Aclaris Therapeutics (ACRS) reported drug candidate ati9494 — research and development project spend of $3.06M in Q2 2026.
- How has Aclaris Therapeutics's drug candidate ati9494 — research and development project spend changed year-over-year?
- Aclaris Therapeutics's drug candidate ati9494 — research and development project spend increased by 250.9% year-over-year, from $871K to $3.06M.
- What does drug candidate ati9494 — research and development project spend mean?
- This metric represents the total direct costs and allocated resources dedicated to the research and development of a specific drug candidate within the clinical-stage pipeline. It captures the financial investment required to advance a therapeutic asset through various stages of preclinical or clinical testing. Tracking this spend provides insight into the company's capital allocation strategy and the relative priority assigned to specific immuno-inflammatory programs.
Ask your AI about Aclaris Therapeutics's drug candidate ati9494 — research and development project spend.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude